Skip to main
IVA
IVA logo

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA, a biopharmaceutical company focused on developing innovative therapies, is advancing its lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. The positive outcomes related to metabolic markers and weight gain observed in high-risk subgroups suggest that lanifibranor could serve as a complementary therapy alongside GLP-1 medications, potentially enhancing its position in the market. Additionally, the company's collaborative research partnerships with AbbVie and BI remain a significant revenue source, while increased confidence in lanifibranor's efficacy and market penetration assumptions further contribute to a favorable outlook for Inventiva's stock.

Bears say

Inventiva SA's financial outlook appears negative due to significant turnover in key regulatory positions such as CEO and CMO, which may disrupt leadership stability and negatively influence share performance. The company reported a net loss of €175.9 million, or €1.62 per share, indicating financial challenges that could hinder future growth and operations. Furthermore, concerns regarding the efficacy and safety of its main clinical program, lanifibranor, in Phase III development, along with the potential for clinical trial failures and delays, present additional risks that may diminish investor confidence and impact stock performance.

Inventiva S.A. (IVA) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Buy based on their latest research and market trends.

According to 6 analysts, Inventiva S.A. (IVA) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.